The Swedish Patent and Registration Office grants Brighter’s patent application.
The Swedish Patent and registration Office last week announced their decision to grant Brighter’s pending patent application (no. 1351376-7) regarding Actiste®. This means that the protection for the fundamental idea behind Actiste is extended by six years and that the company's intellectual property portfolio is broadened and strengthened even further.
– This is a regulatory patent which in practice acts as an extra layer of protection for our key patent, says Truls Sjöstedt, Brighter's CEO and founder. With this new patent we prevent others from making a simplified copy of our Actiste.
For further information, please contact:
Henrik Norström, COO
Phone: 46 733 40 30 45
henrik.norstrom@brighter.se
Truls Sjöstedt, CEO
Phone: 46 709 73 46 00
truls.sjostedt@brighter.se
About Actiste
Brighter’s subscription service solution Actiste® simplifies insulin-treated diabetes by gathering all the most important functions in a connected device with which the diabetic can measure blood sugar levels, set dosage and inject insulin, as well as automatically log and share information.
About Brighter AB (publ)
Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and innovative tools, jDome® and Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care and care for the elderly, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CET on October 12 2016.